Although tumor cells can present the Lass5 epitope and elicit T cells, we believe that generation of tumor-rejective T-cell mediated immunity may require another TAP-independent antigen or multiple antigens for T-cell priming because the Lass5 epitope is presented at a low level in CMT.64 cells. Here, CERS5 is linked to neoplasm.